RxDoctor Payments Data

Edward Rutkovsky, MD

Internal Medicine · New Hyde Park, NYNPI 1881603892

Payments from drug & device makers

$5,814in general payments, 2019–2025

Across 168 payments — averaging $34.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AstraZeneca$536
  • Abbott$470
  • Astellas Pharma US Inc$244
  • Novo Nordisk$244
  • Edwards Lifesciences$241
  • plus $2K from 19 others

What the payments were for

  • Speaking & faculty fees$1002%
  • Food & beverage$5,63297%
  • Education$821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,814 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$2,247,059
Medicare patients
742
Services billed
10,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban241$325,449
EntrestoSacubitril/Valsartan86$132,643
Repatha SureclickEvolocumab72$68,254
XareltoRivaroxaban34$50,083
MultaqDronedarone Hcl12$21,518
Praluent PenAlirocumab20$19,048
BrilintaTicagrelor16$18,207
Rosuvastatin Calcium623$11,703
Metoprolol Succinate440$7,838
Ezetimibe223$6,242
Losartan Potassium291$3,414
Pitavastatin Calcium18$3,275
Clonidine11$3,030
Olmesartan Medoxomil151$2,968
Atorvastatin Calcium295$2,957

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$194$325,449241 claims
NovartisEntresto$128$132,64386 claims
Johnson & JohnsonXarelto$97$50,08334 claims
Sanofi-aventis U.S. LLCMultaq$119$21,51812 claims
AstraZenecaBrilinta$536$18,20716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →